



UNITED STATES PATENT AND TRADEMARK OFFICE

CM
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/698,597	10/31/2003	Leonard G. Presta	39766-0033CP2C2-C1	1656
25213	7590	06/27/2007	EXAMINER	
HELLER EHRLMAN LLP			DAVIS, MINH TAM B	
275 MIDDLEFIELD ROAD			ART UNIT	PAPER NUMBER
MENLO PARK, CA 94025-3506			1642	
MAIL DATE		DELIVERY MODE		
06/27/2007		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief	Application No.	Applicant(s)
	10/698,597	PRESTA ET AL.
	Examiner	Art Unit
	MINH-TAM DAVIS	1642

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 07 May 2007 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

a) The period for reply expires 3 months from the mailing date of the final rejection.
 b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
 (a) They raise new issues that would require further consideration and/or search (see NOTE below);
 (b) They raise the issue of new matter (see NOTE below);
 (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
 (d) They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: _____. (See 37 CFR 1.116 and 41.33(a)).

4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
 5. Applicant's reply has overcome the following rejection(s): _____.
 6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
 7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: none.

Claim(s) objected to: none.

Claim(s) rejected: 6--9, 12.

Claim(s) withdrawn from consideration: 10-11.

AFFIDAVIT OR OTHER EVIDENCE

8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).
 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:
See attached.
 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s). _____.
 13. Other: _____.

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

The amendment of 05/07/07 is not and will not be entered for the following reasons:

- 1) The amendment of claim 6 by addition of SEQ ID Nos requires new search for SEQ ID Nos.
- 2) The submitted sequence listing does not comply with sequence rule.

Sequence Rule

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. 1.821-25 for the reasons set forth on the attached: 1) Sequence Error report and 2) Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 9:00 AM-5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, SHANON FOLEY can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MINH TAM DAVIS
June 09, 2007

/Larry R. Helms/
Supervisory Patent Examiner

Sequence Error / 10/698,597

Sequence Listing could not be accepted due to errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: Fri Jun 08 19:53:52 EDT 2007

Reviewer Comments:

<210> 10

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 10

tgygayatha tgtggynaa rac

23

The "n" at position 18 above needs explanation in the <220>-<223> section; please explain which nucleotide(s) the "n" represents. Same error in Sequences 11 through 13.

<210> 36

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (0)...(0)

<400> 36

If "PEPTIDE" is explaining "<213> Artificial Sequence," it belongs on the <223> line. Per 1.823 of the Sequence Rules, the explanation for "Artificial Sequence" or for "Unknown" goes on the <223> line.

"PEPTIDE" is not a complete explanation for "Artificial Sequence."

Please give source of the genetic material. Same error in Sequences 37,

39-40.

Application No: 10698597

Version No: 2.0

Input Set:

Output Set:

Started: 2007-05-18 12:03:58.977
Finished: 2007-05-18 12:04:01.102
Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 125 ms
Total Warnings: 31
Total Errors: 8
No. of SeqIDs Defined: 45
Actual SeqID Count: 45

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
E 342	'n' position not defined found at POS: 18 SEQID(10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
E 342	'n' position not defined found at POS: 12 SEQID(11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
E 342	'n' position not defined found at POS: 10 SEQID(12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
E 342	'n' position not defined found at POS: 18 SEQID(13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)
W 213	Artificial or Unknown found in <213> in SEQ ID (21)
W 213	Artificial or Unknown found in <213> in SEQ ID (22)
W 213	Artificial or Unknown found in <213> in SEQ ID (23)
W 213	Artificial or Unknown found in <213> in SEQ ID (24)
W 213	Artificial or Unknown found in <213> in SEQ ID (25)

Input Set:

Output Set:

Started: 2007-05-18 12:03:58.977
Finished: 2007-05-18 12:04:01.102
Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 125 ms
Total Warnings: 31
Total Errors: 8
No. of SeqIDs Defined: 45
Actual SeqID Count: 45

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (26)
W 213	Artificial or Unknown found in <213> in SEQ ID (27)
W 213	Artificial or Unknown found in <213> in SEQ ID (28)
W 213	Artificial or Unknown found in <213> in SEQ ID (29) This error has occurred more than 20 times, will not be displayed
E 224	<220>,<223> section required as <213> has Artificial sequence or Unknown in SEQID (36)
E 224	<220>,<223> section required as <213> has Artificial sequence or Unknown in SEQID (37)
E 224	<220>,<223> section required as <213> has Artificial sequence or Unknown in SEQID (39)
E 224	<220>,<223> section required as <213> has Artificial sequence or Unknown in SEQID (40)

SEQUENCE LISTING

<110> Presta, Leonard G.
Shelton, David L.
Urfer, Roman

<120> Human TRK Receptors and Neurotrophic
Factor Inhibitors

<130> 39766-0033-CP2C2C1.US

<140> 10698597
<141> 2003-10-31

<150> 10/698,597
<151> 2003-10-31

<150> 09/724,524
<151> 2000-11-27

<150> 09/156,923
<151> 1998-09-18

<150> 08/359,705
<151> 1994-12-20

<150> 08/286,846
<151> 1994-08-05

<150> 08/215,139
<151> 1994-03-18

<160> 45

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 3194
<212> DNA
<213> Homo sapiens

<400> 1
ggaaggttta aagaagaagc cgcaaagcgc agggaaaggcc tcccgccacg ggtggggaa 60
agcggccggc gcagcgcggg gacaggcaact cgggctggca ctggctgcta gggatgtcg 120
cctggataag gtggcatgga cccgccatgg cgccgctctg gggcttctgc tggctgggt 180
tgggcttctg gaggggccgct ttcgcctgtc ccacgtctg caaatgcagt gcttctcgga 240
tctgggtcag cgacccttct cctggcatcg tggcattcc gagattggag cctaacagtg 300
tagatcctga gaacatcacc gaaatttca tcgaaaccca gaaaaggta gaaatcatca 360
acgaagatga tggtaagct tatgtggac tgagaaatct gacaattgtg gattctggat 420
taaaaattgt ggctcataaaa gcatttctga aaaacagcaa cctgcagcac atcaatttta 480
cccgaaacaa actgacgagt ttgtcttaga aacattccg tcaccttgc ttgtctgaac 540
tgatcctggc gggcaatcca ttacatgct cctgtgacat tatgtggatc aagactctcc 600
aaggagctaa atccagtcca gacactcaagg atttgtactg cctgaatgaa agcagcaaga 660
atattccctt ggcaaaccctg cagataccca atttgtggttt gccatctgca aatctggccg 720
cacctaacctt cactgtggag gaaggaaagt ctatcacatt atcctgttagt gtggcaggtg 780

3194

<210> 2
<211> 822
<212> PRT
<213> *Homo sapiens*

<400> 2

Met Ser Ser Trp Ile Arg Trp His Gly Pro Ala Met Ala Arg Leu Trp	1	5	10	15
Gly Phe Cys Trp Leu Val Val Gly Phe Trp Arg Ala Ala Phe Ala Cys	20	25	30	
Pro Thr Ser Cys Lys Cys Ser Ala Ser Arg Ile Trp Cys Ser Asp Pro	35	40	45	
Ser Pro Gly Ile Val Ala Phe Pro Arg Leu Glu Pro Asn Ser Val Asp	50	55	60	
Pro Glu Asn Ile Thr Glu Ile Phe Ile Ala Asn Gln Lys Arg Leu Glu				

65	70	75	80
Ile Ile Asn Glu Asp Asp Val Glu Ala Tyr Val Gly Leu Arg Asn Leu			
85	90	95	
Thr Ile Val Asp Ser Gly Leu Lys Phe Val Ala His Lys Ala Phe Leu			
100	105	110	
Lys Asn Ser Asn Leu Gln His Ile Asn Phe Thr Arg Asn Lys Leu Thr			
115	120	125	
Ser Leu Ser Arg Lys His Phe Arg His Leu Asp Leu Ser Glu Leu Ile			
130	135	140	
Leu Val Gly Asn Pro Phe Thr Cys Ser Cys Asp Ile Met Trp Ile Lys			
145	150	155	160
Thr Leu Gln Glu Ala Lys Ser Ser Pro Asp Thr Gln Asp Leu Tyr Cys			
165	170	175	
Leu Asn Glu Ser Ser Lys Asn Ile Pro Leu Ala Asn Leu Gln Ile Pro			
180	185	190	
Asn Cys Gly Leu Pro Ser Ala Asn Leu Ala Ala Pro Asn Leu Thr Val			
195	200	205	
Glu Glu Gly Lys Ser Ile Thr Leu Ser Cys Ser Val Ala Gly Asp Pro			
210	215	220	
Val Pro Asn Met Tyr Trp Asp Val Gly Asn Leu Val Ser Lys His Met			
225	230	235	240
Asn Glu Thr Ser His Thr Gln Gly Ser Leu Arg Ile Thr Asn Ile Ser			
245	250	255	
Ser Asp Asp Ser Gly Lys Gln Ile Ser Cys Val Ala Glu Asn Leu Val			
260	265	270	
Gly Glu Asp Gln Asp Ser Val Asn Leu Thr Val His Phe Ala Pro Thr			
275	280	285	
Ile Thr Phe Leu Glu Ser Pro Thr Ser Asp His His Trp Cys Ile Pro			
290	295	300	
Phe Thr Val Lys Gly Asn Pro Lys Pro Ala Leu Gln Trp Phe Tyr Asn			
305	310	315	320
Gly Ala Ile Leu Asn Glu Ser Lys Tyr Ile Cys Thr Lys Ile His Val			
325	330	335	
Thr Asn His Thr Glu Tyr His Gly Cys Leu Gln Leu Asp Asn Pro Thr			
340	345	350	
His Met Asn Asn Gly Asp Tyr Thr Leu Ile Ala Lys Asn Glu Tyr Gly			
355	360	365	
Lys Asp Glu Lys Gln Ile Ser Ala His Phe Met Gly Trp Pro Gly Ile			
370	375	380	
Asp Asp Gly Ala Asn Pro Asn Tyr Pro Asp Val Ile Tyr Glu Asp Tyr			
385	390	395	400
Gly Thr Ala Ala Asn Asp Ile Gly Asp Thr Thr Asn Arg Ser Asn Glu			
405	410	415	
Ile Pro Ser Thr Asp Val Thr Asp Lys Thr Gly Arg Glu His Leu Ser			
420	425	430	
Val Tyr Ala Val Val Val Ile Ala Ser Val Val Gly Phe Cys Leu Leu			
435	440	445	
Val Met Leu Phe Leu Leu Lys Leu Ala Arg His Ser Lys Phe Gly Met			
450	455	460	
Lys Gly Pro Ala Ser Val Ile Ser Asn Asp Asp Asp Ser Ala Ser Pro			
465	470	475	480
Leu His His Ile Ser Asn Gly Ser Asn Thr Pro Ser Ser Ser Glu Gly			
485	490	495	
Gly Pro Asp Ala Val Ile Ile Gly Met Thr Lys Ile Pro Val Ile Glu			
500	505	510	
Asn Pro Gln Tyr Phe Gly Ile Thr Asn Ser Gln Leu Lys Pro Asp Thr			
515	520	525	

Phe Val Gln His Ile Lys Arg His Asn Ile Val Leu Lys Arg Glu Leu
 530 535 540
 Gly Glu Gly Ala Phe Gly Lys Val Phe Leu Ala Glu Cys Tyr Asn Leu
 545 550 555 560
 Cys Pro Glu Gln Asp Lys Ile Leu Val Ala Val Lys Thr Leu Lys Asp
 565 570 575
 Ala Ser Asp Asn Ala Arg Lys Asp Phe His Arg Glu Ala Glu Leu Leu
 580 585 590
 Thr Asn Leu Gln His Glu His Ile Val Lys Phe Tyr Gly Val Cys Val
 595 600 605
 Glu Gly Asp Pro Leu Ile Met Val Phe Glu Tyr Met Lys His Gly Asp
 610 615 620
 Leu Asn Lys Phe Leu Arg Ala His Gly Pro Asp Ala Val Leu Met Ala
 625 630 635 640
 Glu Gly Asn Pro Pro Thr Glu Leu Thr Gln Ser Gln Met Leu His Ile
 645 650 655
 Ala Gln Gln Ile Ala Ala Gly Met Val Tyr Leu Ala Ser Gln His Phe
 660 665 670
 Val His Arg Asp Leu Ala Thr Arg Asn Cys Leu Val Gly Glu Asn Leu
 675 680 685
 Leu Val Lys Ile Gly Asp Phe Gly Met Ser Arg Asp Val Tyr Ser Thr
 690 695 700
 Asp Tyr Tyr Arg Val Gly Gly His Thr Met Leu Pro Ile Arg Trp Met
 705 710 715 720
 Pro Pro Glu Ser Ile Met Tyr Arg Lys Phe Thr Thr Glu Ser Asp Val
 725 730 735
 Trp Ser Leu Gly Val Val Leu Trp Glu Ile Phe Thr Tyr Gly Lys Gln
 740 745 750
 Pro Trp Tyr Gln Leu Ser Asn Asn Glu Val Ile Glu Cys Ile Thr Gln
 755 760 765
 Gly Arg Val Leu Gln Arg Pro Arg Thr Cys Pro Gln Glu Val Tyr Glu
 770 775 780
 Leu Met Leu Gly Cys Trp Gln Arg Glu Pro His Met Arg Lys Asn Ile
 785 790 795 800
 Lys Gly Ile His Thr Leu Leu Gln Asn Leu Ala Lys Ala Ser Pro Val
 805 810 815
 Tyr Leu Asp Ile Leu Gly
 820

<210> 3
 <211> 1870
 <212> DNA
 <213> Homo sapiens

<400> 3
 ggaaggttta aagaagaagc cgcaaagcgc agggaggccc tcccgccacg ggtggggaa 60
 agcggccggc gcagcgcggg gacaggact cgggctggca ctggctycta gggatgtcgt 120
 cctggataag gtggcatgga cccgccatgg cgcggctcg gggcttctgc tggctggttg 180
 tgggttctg gagggccgct ttcgcctgtc ccacgtctcg caaatgcagt gcctctcgga 240
 tctggtgca gaccccttct cctggcatacg tggcattcc gagattggag cctaacagtg 300
 tagatcctga gaacatcacc gaaatttca tcgcaaacca gaaaaggta gaaatcatca 360
 acgaagatga tggtaagct tatgtggac tgagaaatct gacaattgtg gattctggat 420
 taaaatttgt ggctcataaa gcatttctga aaaacaccaa cctgcagcac atcaattta 480
 cccgaaacaa actgacgagt ttgtcttaga aacattccg tcaccttgac ttgtctgaac 540
 tgatcctgggt gggcaatcca tttacatgtc cctgtgacat tatgtggatc aagactctcc 600
 aagaggctaa atccagtcca gacactcagg atttgtactg cctgaatgaa agcagcaaga 660

<210> 4
<211> 477
<212> PRT
<213> Home sapiens

<400> 4
 Met Ser Ser Trp Ile Arg Trp His Gly Pro Ala Met Ala Arg Leu Trp
 1 5 10 15
 Gly Phe Cys Trp Leu Val Val Gly Phe Trp Arg Ala Ala Phe Ala Cys
 20 25 30
 Pro Thr Ser Cys Lys Cys Ser Ala Ser Arg Ile Trp Cys Ser Asp Pro
 35 40 45
 Ser Pro Gly Ile Val Ala Phe Pro Arg Leu Glu Pro Asn Ser Val Asp
 50 55 60
 Pro Glu Asn Ile Thr Glu Ile Phe Ile Ala Asn Gln Lys Arg Leu Glu
 65 70 75 80
 Ile Ile Asn Glu Asp Asp Val Glu Ala Tyr Val Gly Leu Arg Asn Leu
 85 90 95
 Thr Ile Val Asp Ser Gly Leu Lys Phe Val Ala His Lys Ala Phe Leu
 100 105 110
 Lys Asn Ser Asn Leu Gln His Ile Asn Phe Thr Arg Asn Lys Leu Thr
 115 120 125
 Ser Leu Ser Arg Lys His Phe Arg His Leu Asp Leu Ser Glu Leu Ile
 130 135 140
 Leu Val Gly Asn Pro Phe Thr Cys Ser Cys Asp Ile Met Trp Ile Lys
 145 150 155 160
 Thr Leu Gln Glu Ala Lys Ser Ser Pro Asp Thr Gln Asp Leu Tyr Cys
 165 170 175
 Leu Asn Glu Ser Ser Lys Asn Ile Pro Leu Ala Asn Leu Gln Ile Pro
 180 185 190
 Asn Cys Gly Leu Pro Ser Ala Asn Leu Ala Ala Pro Asn Leu Thr Val
 195 200 205
 Glu Glu Gly Lys Ser Ile Thr Leu Ser Cys Ser Val Ala Gly Asp Pro
 210 215 220
 Val Pro Asn Met Tyr Trp Asp Val Gly Asn Leu Val Ser Lys His Met

225	230	235	240
Asn Glu Thr Ser His Thr Gln Gly Ser Leu Arg Ile Thr Asn Ile Ser			
245	250	255	
Ser Asp Asp Ser Gly Lys Gln Ile Ser Cys Val Ala Glu Asn Leu Val			
260	265	270	
Gly Glu Asp Gln Asp Ser Val Asn Leu Thr Val His Phe Ala Pro Thr			
275	280	285	
Ile Thr Phe Leu Glu Ser Pro Thr Ser Asp His His Trp Cys Ile Pro			
290	295	300	
Phe Thr Val Lys Gly Asn Pro Lys Pro Ala Leu Gln Trp Phe Tyr Asn			
305	310	315	320
Gly Ala Ile Leu Asn Glu Ser Lys Tyr Ile Cys Thr Lys Ile His Val			
325	330	335	
Thr Asn His Thr Glu Tyr His Gly Cys Leu Gln Leu Asp Asn Pro Thr			
340	345	350	
His Met Asn Asn Gly Asp Tyr Thr Leu Ile Ala Lys Asn Glu Tyr Gly			
355	360	365	
Lys Asp Glu Lys Gln Ile Ser Ala His Phe Met Gly Trp Pro Gly Ile			
370	375	380	
Asp Asp Gly Ala Asn Pro Asn Tyr Pro Asp Val Ile Tyr Glu Asp Tyr			
385	390	395	400
Gly Thr Ala Ala Asn Asp Ile Gly Asp Thr Thr Asn Arg Ser Asn Glu			
405	410	415	
Ile Pro Ser Thr Asp Val Thr Asp Lys Thr Gly Arg Glu His Leu Ser			
420	425	430	
Val Tyr Ala Val Val Val Ile Ala Ser Val Val Gly Phe Cys Leu Leu			
435	440	445	
Val Met Leu Phe Leu Leu Lys Leu Ala Arg His Ser Lys Phe Gly Met			
450	455	460	
Lys Gly Phe Val Leu Phe His Lys Ile Pro Leu Asp Gly			
465	470	475	

<210> 5
<211> 2715
<212> DNA
<213> Homo sapiens

<400> 5
ggatccgcgt cggagatgga tgtctcttt tgcccagcca agtgttagttt ctggcggatt 60
ttcttgctgg gaagcgtctg gctggactat gtgggctccg tgctggcttg ccctgcaaat 120
tgtgtctgca gcaagactga gatcaattgc cggcgccgg acgatggaa cctttcccc 180
ctccttggaaag ggcaggattc agggAACAGC aatggAACG CCAATATCAA CATCACGGAC 240
atct